

CONTENTS

Preface	v
----------------------	----------

List of Contributors	xvii
-----------------------------------	-------------

1. Principles of Human Tumor Virology.....	1
George Klein and Daniel DiMaio	

1.1. Introduction	1
1.2. Precedents in Animals.....	1
1.3. Human Tumor Viruses.....	2
1.3.1. Human Papillomaviruses	3
1.3.2. Hepatitis Viruses	3
1.3.3. Epstein–Barr Virus.....	3
1.3.4. Human Herpesvirus-8	4
1.3.5. Human T Lymphotropic Virus Type I.....	4
1.3.6. SV40 as a Potential Human Tumor Virus	4
1.3.7. Viral Tumors in the Developing World	4
1.4. Mechanisms of Viral Tumorigenesis	5
1.5. Immunity and Tumor Viruses.....	6
1.6. Prospects for Prevention and Treatment.....	7
1.7. Conclusions	8

2. History of Papillomavirus Research.....	13
Douglas R. Lowy	

2.1. Introduction	13
2.2. The 1930s and 1940s: Biology of the Shope Papillomavirus and Other Animal Papillomaviruses	14
2.3. The 1950s and 1960s: Cell Differentiation and Virus Replication.....	16
2.4. The 1970s to the Early 1990s: Viral Genetics and the Emergence of HPV as a Medically Important Virus	17

3. Phylogeny and Typing of Papillomaviruses.....	29
Hans-Ulrich Bernard	
3.1. Introduction	29
3.2. Papillomaviridae: A Taxon Separate from the Polyomaviruses	31
3.3. Novel Attempts to Improve the Nomenclature of Groups of Papillomavirus (PV) Types	31
3.3.1. The Genus	31
3.3.2. Papillomavirus “Species”	33
3.4. Papillomavirus Types, the Natural Taxonomic Entities in Molecular and Clinical Investigations	36
3.5. Papillomavirus Subtypes	36
3.6. Papillomavirus Variants	37
3.7. Papillomavirus Typing in Research and Clinical Practice	38
3.8. General Considerations Regarding the Evolution of Papillomaviruses	39
3.9. Evolution of Papillomaviruses: The Time Scale	40
3.10. Pathogenicity Versus Latency	41
4. The Differentiation-Dependent Life Cycle of Human Papillomaviruses in Keratinocytes	45
Choogho Lee and Laimonis A. Laimins	
4.1. Introduction	45
4.2. Life Cycle of HPVs	45
4.3. Methods to Study the HPV Life Cycle	46
4.4. Genome Organization and Gene Products of HPVs	49
4.5. Control of HPV Transcription	52
4.6. Differentiation-Dependent Mechanisms to Regulate HPV DNA Replication	54
4.7. Roles of the HPV E6 and E7 Proteins in the Viral Life Cycle	55
4.8. Effects of HPVs on Epithelial Differentiation	57
4.9. Conclusion	58
5. Papillomavirus Structure and Assembly	69
Robert L. Garcea and Xiaojiang Chen	
5.1. Introduction	69
5.2. Structure Determination	70
5.3. L1 Monomer	72
5.4. Disulfide Bonds	73
5.5. Pentamer–Pentamer Contacts	74
5.6. Surface Loops and Epitopes	76
5.7. L1 Self-Assembly	77
5.8. Pseudovirion Synthesis	79
5.9. Role of L2	80

5.10. Nuclear Localization and DNA Binding of L1 and L2	81
5.11. Summary.....	83
6. Viral Entry and Receptors	89
Rolf E. Streeck, Hans-Christoph Selinka, and Martin Sapp	
6.1. Introduction	89
6.2. Binding to the Cell Surface	91
6.3. Contribution of L2 to Viral Entry	96
6.4. A Passage to Cytoplasm and Nucleus	96
6.5. Conclusion.....	101
7. Human Papillomavirus Transcription.....	109
Louise T. Chow and Thomas R. Broker	
7.1. Introduction	109
7.1.1. Papillomaviridae.....	109
7.1.2. Papillomavirus Infections	110
7.1.3. HPV Genome Organization	110
7.2. Overview of Viral Transcription in Productive Infections	112
7.3. Viral RNA Mapping in Warty Lesions	113
7.4. Organotypic Raft Cultures of Primary Human Keratinocytes as a Model System to Study HPVs.....	118
7.4.1. Viral RNAs in Organotypic Model Systems.....	119
7.5. Where in the Stratified Squamous Epithelium Are E6 and E7 Proteins Expressed in Productively Infected Lesions?.....	121
7.6. Mechanisms That Control the Expression of the E6 and E7 Proteins	123
7.6.1. Transcriptional Regulation.....	123
7.6.2. Post-Transcriptional Regulation	124
7.7. What Is the Role of E2?	125
7.8. Why Are There So Many Promoters and Spliced Transcripts?.....	126
7.9. Basis For HPV Oncogenesis.....	128
7.9.1. Transcription in Carcinomas and Cervical Carcinoma Cell Lines	128
7.9.2. Are There Additional Viral Proteins Contributing to Viral Carcinogenesis?	129
7.10. Concluding Remarks	131
8. DNA Replication of Papillomaviruses	145
Arne Stenlund	
8.1. Introduction	145
8.2. Assays for Replication of Viral DNA	146
8.2.1. Short-Term Replication Assays	146
8.2.2. Viral DNA Replication In Vitro.....	147

8.2.3. Is There More Than One Way to Replicate Viral DNA?	147
8.3. Plasmid Maintenance	148
8.4. The Relationship Between DNA Replication and Morphological Transformation	148
8.5. The Basic Requirements for DNA Replication: E1, E2, and Ori.....	149
8.6. The Requirement for Cellular Factors in Viral DNA Replication	150
8.7. Description of the Parts	151
8.7.1. The Viral Origin of DNA Replication	151
8.8. Understanding the E1 Protein	154
8.8.1. The E1 DBD	154
8.8.2. Activities Associated with the E1 Protein.....	157
8.9. The Interaction Between E1 and Cellular and Viral Factors Involved in DNA Replication	160
8.9.1. Modifications of E1	160
8.9.2. The Role of E2 in DNA Replication.....	161
8.10. A Conflict Between Specific and Nonspecific DNA-Binding Activities in E1	162
8.11. A Mechanism of Action for E2	164
8.12. The E1-E2 Complex is a Precursor for Formation of Larger E1 Complexes.....	164
8.13. The Viral DNA Replication Machinery as a Target for Small Molecule Intervention.....	166
9. Papillomavirus E5 Proteins.....	175
Daniel DiMaio	
9.1. Introduction	175
9.2. The BPV1 E5 Protein	175
9.2.1. The Cellular Platelet-Derived Growth Factor β -Receptor as a Target of the BPV1 E5 Protein.....	176
9.2.2. Model for the Transmembrane Interaction Between the BPV1 E5 Protein and the PDGF β -Receptor.....	178
9.2.3. Selection and Analysis of Small Transmembrane Transforming Proteins Modeled on the BPV1 E5 Protein	179
9.2.4. Alternative Models of BPV1 E5 Transformation	179
9.3. The BPV4 E5 Protein	180
9.4. The Human Papillomavirus E5 Proteins	181
9.4.1. HPV16 E5 Protein and the EGF Receptor.....	182
9.5. Interaction of E5 Proteins with the Vacuolar H^+ -ATPase	183
9.6. E5 Proteins and Major Histocompatibility Antigen Expression.....	185
9.7. Effects of E5 Proteins on Apoptosis	186

9.8. Role of E5 Proteins in the Virus Life Cycle and Carcinogenesis	187
9.9. Conclusions	188
10. Human Papillomavirus E6 and E7 Oncogenes.....	197
Karl Munger, Peter Howley, and Daniel DiMaio	
10.1. Introduction	197
10.2. Papillomavirus E6 Proteins.....	197
10.2.1. Biochemical Characterization of Papillomavirus E6 Proteins	198
10.2.2. Human Papillomavirus E6 Proteins.....	199
10.2.3. Bovine Papillomavirus E6 Protein	206
10.3. Papillomavirus E7 Proteins.....	207
10.3.1. Biochemical Characterization of HPV E7 Proteins	207
10.3.2. Biological Activities of the E7 Protein	209
10.3.3. Association of E7 with the Retinoblastoma Tumor Suppressor pRB and the Related p107 and p130 Pocket Proteins.....	210
10.3.4. Association of E7 with Histone-Modifying Enzymes	212
10.3.5. Destabilization of pRB, p107, and p130	213
10.3.6. HPV E7 and the p53 Tumor Suppressor.....	214
10.3.7. Interactions of HPV E7 with Components of the Cell-Cycle Machinery	215
10.3.8. Modulation of Cytostatic Cytokine Signaling by HPV E7	216
10.3.9. Effects of HPV E7 on Cellular Metabolism	218
10.3.10. HPV E7 and Chromosomal Instability	218
10.4. Role of the HPV E6 and E7 Genes in Survival and Proliferation of Cancer Cells	220
10.4.1. Antisense and Related Technologies That Reduce HPV RNA in Cervical Cancer Cells	220
10.4.2. Small Molecules and Peptides That Inhibit HPV Expression or Activity in Cervical Carcinoma Cells	221
10.4.3. Papillomavirus E2 Protein as a Repressor of HPV Expression in Cervical Carcinoma Cells	222
10.4.4. HPV-Independent Effects of the E2 Protein	224
10.5. HPV E6 and E7 Proteins as Potential Therapeutic Targets.....	225
11. In Vivo Models for the Study of Animal and Human Papillomaviruses	253
Paul F. Lambert and Anne E. Griep	
11.1. Introduction	253
11.2. Animal Papillomaviruses	253

11.2.1. Rabbit Papillomaviruses	254
11.2.2. Bovine Papillomaviruses.....	254
11.2.3. Other Animal Papillomavirus	255
11.2.4. Use of Animal Papillomaviruses in the Analysis of Prophylactic Vaccines	255
11.3. Transgenic Mouse Models for the Study of Human Papillomaviruses.....	257
11.3.1. BPV Transgenic Mice.....	258
11.3.2. HPV Transgenic Mice	258
11.4. Mechanistic Studies of E6 in Transgenic Mouse Models.....	260
11.5. Mechanistic Studies of E7 in Transgenic Mouse Models.....	261
11.6. Transgenic Mouse Studies on the Role of HPV in Cervical Cancer in Transgenic Mice	263
11.7. Use of HPV Transgenic Mice as Preclinical Models for Testing New Modalities for Preventing or Treating Cervical Cancer	265
11.8. Additional Mouse Models for HPV-Associated Neoplasia	266
11.9. Summary.....	267
 12. The Humoral Immune Response to Human Papillomavirus	 277
Erin M. Egelkrout and Denise A. Galloway	
12.1. Introduction	277
12.2. Early Work on Identification of Humoral Immune Response	277
12.3. Serological Assays Using Proteins and Synthetic Peptides	278
12.4. VLPs/Capsomers	280
12.4.1. Introduction/Overview of Serological Methods.....	280
12.5. Capsid/Capsomer/VLP Production	280
12.5.1. Serological Assays	281
12.5.2. Natural History and Serological Response to HPV Capsid Proteins.....	284
12.6. Studies Defining HPV Virion Epitopes.....	290
12.6.1. Details of Known L1 Epitopes	290
12.6.2. Antibodies to the L2 Protein	293
12.7. Conclusions and Future Perspectives	293
 13. Cell-Mediated Immune Responses to Human Papillomavirus	 313
Gretchen Eiben Lyons, Michael I. Nishimura, and W. Martin Kast	
13.1. Introduction	313
13.2. Virally Induced Tumors	313
13.3. Immunology to Viral Assault	315

13.4. The Importance of Cell-Mediated Immunity	315
13.5. Immune Activation Against HPV Infection	317
13.6. Immune Evasion by HPV	318
13.6.1. MHC Regulation	319
13.6.2. Modulation of Antigen Presentation.....	320
13.6.3. Loss of T-Cell-Receptor ζ -Chain Expression	320
13.6.4. Subversion of HPV by Cytokines	321
13.7. The Importance of the CD4 Helper Response	323
13.8. Genetic Susceptibility to HPV Associated Carcinogenesis	324
13.9. Conclusions	325
 14. Papillomavirus Vaccines.....	337
John Schiller	
14.1. Introduction	337
14.2. Therapeutic Vaccines	337
14.2.1. Introduction	337
14.2.2. Lessons from Natural History Studies.....	341
14.2.3. Animal Models for Therapeutic HPV Vaccines	341
14.2.4. Therapeutic Clinical Trials	343
14.2.5. Type Specificity	345
14.2.6. Why Haven't Therapeutic HPV Vaccines Been More Successful?.....	346
14.2.7. Conclusions: Therapeutic Vaccines.....	347
14.3. Prophylactic Vaccines	347
14.3.1. Introduction	347
14.3.2. Preclinical Studies.....	348
14.3.3. Clinical Trials.....	349
14.3.4. Remaining Scientific Questions.....	353
14.3.5. Target Populations	354
14.3.6. Implementation Issues.....	355
14.3.7. Second-Generation Vaccines	357
14.3.8. Conclusions: Prophylactic Vaccines.....	360
 15. Clinical Assessment, Therapies, New Tests, and Algorithms	371
Christopher P. Crum, and Ralph M. Richart	
15.1. Introduction	371
15.2. Human Papillomaviruses and Risk.....	371
15.2.1. HPV Infection Is the Principal Cause of Cervical Neoplasia.....	371
15.2.2. HPV Infection Is Extremely Common in Sexually Active, Reproductive-Age Women.....	372

15.2.3.	There Is a Broad Gradient of Risk Imposed by Cancer-Associated (High-Risk) HPV Types, with HPV Type 16 Conferring the Greatest Risk; Low-Risk HPV Types May Confer Risk as Surrogate Markers of At-Risk Behavior	372
15.2.4.	A Woman Harboring a Persistent High-Risk HPV Type in Her Genital Tract Is at Risk for Developing a High-Grade Squamous Intraepithelial Lesion (HSIL)	372
15.2.5.	Women Infected by HIV Are at Increased Risk of CIN.....	373
15.2.6.	Sexual History of the Male Sexual Partner Influences the Risk of Cervical Neoplasia	373
15.3.	HPV DNA Testing	374
15.3.1.	Screening.....	374
15.3.2.	Application to the Management of Atypical Squamous Cells of Undetermined Significance	375
15.3.3.	Management of Patients with Atypical Glandular Cells.....	376
15.3.4.	Problem-Oriented HPV DNA Testing.....	377
15.3.5.	Potential Risks of HPV DNA Testing.....	378
15.3.6.	Type-Specific HPV DNA Testing	380
15.4.	Conventional Approaches to Pre-Invasive HPV-Related Diseases	380
15.4.1.	Cytology- and Pathology-Based Management	380
15.5.	New Therapeutic Approaches	381
15.5.1.	Aldara	381
15.5.2.	Immunotherapeutics	381
15.5.3.	Preventive Vaccines.....	382
15.6.	Summary.....	382

16. Possible Worldwide Impact of Prevention of Human Papillomavirus Infection 387

Sonia R. Pagliusi, M. Teresa Aguado,
and D. Maxwell Parkin

16.1.	Introduction	387
16.1.1.	HPV Infections Worldwide and Related Human Diseases	387
16.1.2.	Genital HPV Infections and Clinical Outcomes	388
16.1.3.	Prevalence and Incidence of HPV Infections	389
16.2.	HPV Infection as a Cause of Cancer.....	390
16.2.1.	Cancer of the Cervix Uteri	390
16.2.2.	Other Ano-Genital Cancers	393

16.2.3. How Much Cancer Globally Is Related to Infection with HPV?	394
16.3. Primary and Secondary Prevention Strategies	396
16.3.1. Primary Prevention Strategies	396
16.3.2. Secondary Prevention Strategies	401
16.4. Conclusion.....	406
Index	415

The Papillomaviruses

Garcea, R.; DiMaio, D. (Eds.)

2007, XIX, 419 p., Hardcover

ISBN: 978-0-387-36522-0